.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Boehringer Ingelheim
Merck
Federal Trade Commission
Teva
US Department of Justice
Accenture
Express Scripts
Mallinckrodt
Julphar

Generated: November 21, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,242,294

« Back to Dashboard

Which drugs does patent 8,242,294 protect, and when does it expire?


Patent 8,242,294 protects KYBELLA and is included in one NDA.

This patent has forty-five patent family members in twenty-six countries.

Summary for Patent: 8,242,294

Title:Synthetic bile acid compositions and methods
Abstract: Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.
Inventor(s): Moriarty; Robert M. (Michiana Shores, IN), David; Nathaniel E. (Los Angeles, CA), Mahmood; Nadir Ahmeduddin (Calabasas, CA)
Assignee: Kythera Biopharmaceuticals, Inc. (Calabasas, CA)
Application Number:12/541,045
Patent Claim Types:
see list of patent claims
Compound;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Kythera Biopharms
KYBELLA
deoxycholic acid
SOLUTION;SUBCUTANEOUS206333-001Apr 29, 2015RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,242,294

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,902,387Preparation of bile acids and intermediates thereof► Subscribe
8,367,852Preparation of bile acids and intermediates thereof► Subscribe
8,461,140Synthetic bile acid compositions and methods► Subscribe
9,050,349Synthetic bile acid compositions and methods► Subscribe
8,883,770Synthetic bile acid compositions and methods► Subscribe
9,150,607Preparation of bile acids and intermediates thereof► Subscribe
9,636,349Synthetic bile acid compositions and methods► Subscribe
9,522,155Synthetic bile acid compositions and methods► Subscribe
8,546,367Synthetic bile acid compositions and methods► Subscribe
8,362,285Preparation of bile acids and intermediates thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,242,294

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina067440► Subscribe
Australia2008265721► Subscribe
BrazilPI0813140► Subscribe
Canada2690841► Subscribe
Canada2789109► Subscribe
China101711254► Subscribe
China106083969► Subscribe
China106146594► Subscribe
Costa Rica11174► Subscribe
Costa Rica20170070► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Cantor Fitzgerald
Colorcon
Daiichi Sankyo
Harvard Business School
US Department of Justice
Merck
McKinsey
Covington
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot